Market Research Logo

Dementia - Pipeline Review, H2 2018

Dementia - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dementia - Pipeline Review, H2 2018, provides an overview of the Dementia (Central Nervous System) pipeline landscape.

Dementia is the loss of mental functions such as thinking, memory, and reasoning that is severe enough to interfere with a person's daily functioning. Symptoms include memory loss, hallucinations, agitation, personality changes and difficulty with coordination and motor functions. Risk factors include age, smoking, obesity, high blood pressure, inflammation and cardiovascular diseases.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dementia - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Dementia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dementia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dementia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 18, 14, 1, 49, 16 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 11 and 3 molecules, respectively.

Dementia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Dementia (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Dementia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Dementia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Dementia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Dementia (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Dementia (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Dementia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Dementia - Overview 7
Dementia - Therapeutics Development 8
Dementia - Therapeutics Assessment 23
Dementia - Companies Involved in Therapeutics Development 33
Dementia - Drug Profiles 60
Dementia - Dormant Projects 270
Dementia - Discontinued Products 275
Dementia - Product Development Milestones 277
Appendix
List of Tables
Number of Products under Development for Dementia, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..3), H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Products under Development by Companies, H2 2018 (Contd..3), H2 2018
Products under Development by Companies, H2 2018 (Contd..4), H2 2018
Products under Development by Companies, H2 2018 (Contd..5), H2 2018
Products under Development by Companies, H2 2018 (Contd..6), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Target, H2 2018 (Contd..1), H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..1), H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Dementia - Pipeline by Acadia Pharmaceuticals Inc, H2 2018
Dementia - Pipeline by Acorda Therapeutics Inc, H2 2018
Dementia - Pipeline by Actinogen Medical Ltd, H2 2018
Dementia - Pipeline by Adamed Sp z oo, H2 2018
Dementia - Pipeline by AgeneBio Inc, H2 2018
Dementia - Pipeline by Alector LLC, H2 2018
Dementia - Pipeline by Allergan Plc, H2 2018
Dementia - Pipeline by Anavex Life Sciences Corp, H2 2018
Dementia - Pipeline by Asceneuron SA, H2 2018
Dementia - Pipeline by Axon Neuroscience SE, H2 2018
Dementia - Pipeline by Axovant Sciences Ltd, H2 2018
Dementia - Pipeline by Biogen Inc, H2 2018
Dementia - Pipeline by BioXcel Therapeutics Inc, H2 2018
Dementia - Pipeline by Boehringer Ingelheim GmbH, H2 2018
Dementia - Pipeline by Bolder Biotechnology Inc, H2 2018
Dementia - Pipeline by Cortice Biosciences Inc, H2 2018
Dementia - Pipeline by CSPC NBP Pharmaceutical Co Ltd, H2 2018
Dementia - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2018
Dementia - Pipeline by Denali Therapeutics Inc, H2 2018
Dementia - Pipeline by DiaMedica Therapeutics Inc, H2 2018
Dementia - Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittel, H2 2018
Dementia - Pipeline by Echo Pharmaceuticals BV, H2 2018
Dementia - Pipeline by Eisai Co Ltd, H2 2018
Dementia - Pipeline by Eli Lilly and Co, H2 2018
Dementia - Pipeline by Ensol Biosciences Inc, H2 2018
Dementia - Pipeline by EVER Neuro Pharma GmbH, H2 2018
Dementia - Pipeline by H. Lundbeck AS, H2 2018
Dementia - Pipeline by Heptares Therapeutics Ltd, H2 2018
Dementia - Pipeline by Hyundai Pharmaceutical Co Ltd, H2 2018
Dementia - Pipeline by Immungenetics AG, H2 2018
Dementia - Pipeline by Intellect Neurosciences Inc, H2 2018
Dementia - Pipeline by Intra-Cellular Therapies Inc, H2 2018
Dementia - Pipeline by IRLAB Therapeutics AB, H2 2018
Dementia - Pipeline by Ironwood Pharmaceuticals Inc, H2 2018
Dementia - Pipeline by Johnson & Johnson, H2 2018
Dementia - Pipeline by M3 Biotechnology Inc, H2 2018
Dementia - Pipeline by MediPost Co Ltd, H2 2018
Dementia - Pipeline by Neuraltus Pharmaceuticals Inc, H2 2018
Dementia - Pipeline by Neurimmune Holding AG, H2 2018
Dementia - Pipeline by NeuroScientific Biopharmaceuticals Pty Ltd, H2 2018
Dementia - Pipeline by Oryzon Genomics SA, H2 2018
Dementia - Pipeline by P2D Inc, H2 2018
Dementia - Pipeline by Pacific Northwest Biotechnology LLC, H2 2018
Dementia - Pipeline by Pharmasum Therapeutics AS, H2 2018
Dementia - Pipeline by Prana Biotechnology Ltd, H2 2018
Dementia - Pipeline by ProMIS Neurosciences Inc, H2 2018
Dementia - Pipeline by Prothena Corp Plc, H2 2018
Dementia - Pipeline by Rodin Therapeutics Inc, H2 2018
Dementia - Pipeline by Sage Therapeutics Inc, H2 2018
Dementia - Pipeline by SanBio Inc, H2 2018
Dementia - Pipeline by Sinil Pharmaceutical Co Ltd, H2 2018
Dementia - Pipeline by Stemedica Cell Technologies Inc, H2 2018
Dementia - Pipeline by Suven Life Sciences Ltd, H2 2018
Dementia - Pipeline by Theranexus SAS, H2 2018
Dementia - Pipeline by Vicore Pharma AB, H2 2018
Dementia - Pipeline by Voyager Therapeutics Inc, H2 2018
Dementia - Pipeline by WAVE Life Sciences Ltd, H2 2018
Dementia - Pipeline by WhanIn Pharmaceutical Co Ltd, H2 2018
Dementia - Dormant Projects, H2 2018
Dementia - Dormant Projects, H2 2018 (Contd..1), H2 2018
Dementia - Dormant Projects, H2 2018 (Contd..2), H2 2018
Dementia - Dormant Projects, H2 2018 (Contd..3), H2 2018
Dementia - Dormant Projects, H2 2018 (Contd..4), H2 2018
Dementia - Discontinued Products, H2 2018
Dementia - Discontinued Products, H2 2018 (Contd..1), H2 2018
List of Figures
Number of Products under Development for Dementia, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Top 10 Routes of Administration, H2 2018
Number of Products by Stage and Top 10 Routes of Administration, H2 2018
Number of Products by Top 10 Molecule Types, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report